The 33-Mer Gluten Peptide: Why This Fragment Is So Toxic in Celiac Disease

A 33-amino-acid gliadin peptide (the '33-mer'), naturally produced by gastrointestinal digestion of wheat gluten, is an exceptionally potent T cell stimulator in celiac disease. It contains six overlapping copies of three T cell epitopes and, after modification by tissue transglutaminase (TG2), binds with high affinity to the HLA-DQ2 immune molecule. Remarkably, the 33-mer doesn't need to be further processed inside immune cells — it can be presented to T cells directly, even by chemically fixed (non-living) antigen-presenting cells. It also binds DQ2 optimally at pH 6.3, promoting extracellular binding.

In vitro immunology study using T cells derived from celiac disease intestinal biopsies. The 33-mer peptide was tested for DQ2 binding affinity, T cell stimulatory potency, and antigen-presenting cell (APC) requirements using live and glutaraldehyde-fixed EBV-transformed B cells and dendritic cells. Binding pH profiles were characterized.

This study revealed why one specific peptide fragment from wheat gluten is so toxic to people with celiac disease. The 33-mer is uniquely resistant to digestion, contains multiple T cell epitopes packed into a single fragment, and doesn't need immune cell processing to trigger an attack. Understanding this 'super-antigen' peptide has been central to developing celiac disease therapies, including enzyme supplements designed to break it down and peptide-based tolerance therapies.

The discovery of the 33-mer as the key immunotoxic fragment in celiac disease has driven multiple therapeutic approaches. Enzyme therapies like latiglutenase are being developed specifically to break down this resistant peptide. Peptide vaccine approaches (like Nexvax2, which was tested in clinical trials) used portions of the 33-mer to try to induce immune tolerance. Understanding this single peptide has been foundational to nearly every celiac disease therapeutic strategy developed since.

In vitro study using celiac patient-derived T cells — does not address in vivo immune dynamics. Only HLA-DQ2-associated celiac disease studied (most but not all celiac patients carry DQ2). The study characterizes the 33-mer's properties but does not test therapeutic interventions.